October 29, 2020

The Niche

Knoepfler lab stem cell blog

Striking improvement in vision in one ACT trial participant

advanced cell technologyAdvanced Cell Technology (ACT) has confirmed that one of the patient in a clinical trial that it is running for treatment of macular degeneration, the leading cause of blindness worldwide, has shown a striking improvement in vision.

The patient reportedly had 20/400 vision prior to treatment and now has 20/40 vision after treatment.

ACT uses an embryonic stem cell-based therapy composed of retinal pigmented epithelial cells.

The improvement in vision is unlikely to be due to chance, however it is still unclear how promising this might be from a larger perspective. Indeed the company itself says:

ACT cautions that the improvement in the patient’s vision reported in this press release may not be indicative of future results of clinical trials of the RPE cells derived from hESCs.ACTC stock

Still, this is at the very least, encouraging news, but one patient does not tell the whole story.

For more, check out my interview with ACT CEO Gary Rabin.

The stock is up 17% just today so far.

I do not own stock in ACTC or other related companies.

%d bloggers like this: